Review
Obstetrics & Gynecology
James B. Bussel, Emilie L. Vander Haar, Richard L. Berkowitz
Summary: Advances in managing fetal and neonatal alloimmune thrombocytopenia may include screening all antepartum patients, noninvasively testing fetal human platelet antigen 1 genotype, developing a prophylactic product equivalent to Rh immune globulin, and creating neonatal Fc receptor inhibitors as potential therapies.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Hematology
Assaf Barg, Lilach Bonstein
Summary: This review discusses the advances in the field of fetal and neonatal alloimmune thrombocytopenia (FNAIT), including new methods for prenatal diagnosis and treatment. Topics explored include noninvasive prenatal testing, novel therapeutic options developed through the use of mouse models, and research on the biological characteristics of alloantibodies and their association with the risk of fetal bleeding.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Article
Biochemistry & Molecular Biology
Thijs W. de Vos, Dian Winkelhorst, Hans J. Baelde, Kyra L. Dijkstra, Rianne D. M. van Bergen, Lotte E. van der Meeren, Peter G. J. Nikkels, Leendert Porcelijn, C. Ellen van der Schoot, Gestur Vidarsson, Michael Eikmans, Rick Kapur, Carin van der Keur, Leendert A. Trouw, Dick Oepkes, Enrico Lopriore, Marie-Louise P. van der Hoorn, Manon Bos, Masja de Haas
Summary: This study found that untreated FNAIT cases showed more C4d deposition in the placenta, which may impact placental function and fetal growth. Histopathological examination revealed a certain proportion of placental delayed maturation in these cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Huiying Zhi, Douglas Sheridan, Debra K. Newman, Peter J. Newman
Summary: The study found that HPA-1a-specific antibody therapy can prevent FNAIT by quickly eliminating circulating HPA-1a(+) platelets and preventing the production of alloantibodies. In mouse experiments, prophylactic treatment with HPA-1a antibodies significantly improved platelet counts and prevented bleeding symptoms.
Article
Hematology
Huiying Zhi, Maria T. Ahlen, Bjorn Skogen, Debra K. Newman, Peter J. Newman
Summary: Fetal/neonatal alloimmune thrombocytopenia is a life-threatening bleeding disorder caused by maternal antibodies attacking paternally inherited antigens on fetal platelets. By establishing an antigen-specific mouse model, further research and development of treatment methods can be conducted.
Article
Hematology
Christof Geisen, Mette Kjaer, Erika Fleck, Bjorn Skogen, Roisin Armstrong, Frank Behrens, Zubin Bhagwagar, Susanne Braeuninger, Anette Mortberg, Klaus Juel Olsen, Stephan Martin Gaston Schaefer, Carmen Walter, Erhard Seifried, Agneta Wikman, Jens Kjeldsen-Kragh, Michaela Koehm
Summary: This study investigated whether a single dose of anti-HPA-1a could accelerate the elimination of HPA-1ab platelets in healthy participants. The results showed that anti-HPA-1a significantly accelerated the elimination of HPA-1ab platelets in all participants, supporting its potential use in the prevention and treatment of FNAIT in pregnant women at risk.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Zachary A. Colvin, Jennifer Schiller, Shirng-Wern Tsaih, Ruchika Sharma, Rachael F. Grace, Jennifer J. McIntosh, Brian R. Curtis
Summary: This study examined whether suspected cases of fetal and neonatal alloimmune thrombocytopenia (FNAIT) without maternal human platelet antigens (HPA) antibodies had different human leukocyte antigen (HLA) antibody strength and specificity compared to controls. The results showed that FNAIT cases had significantly higher HLA antibody strength and broader HLA antibody specificity compared to matched controls.
Article
Hematology
Kristine Matusiak, Christopher J. Patriquin, Stacy Deniz, Nancy Dzaja, James W. Smith, Grace Wang, Ishac Nazy, John G. Kelton, Donald M. Arnold
Summary: This study investigated clinical and laboratory predictors of severe FNAIT and found that maternal antibodies to HPA were the only independent predictor of severe FNAIT in subsequent pregnancies. However, one infant had a severe FNAIT recurrence without maternal antibodies, highlighting the need for improved prevention and treatment strategies.
Article
Immunology
Zoltan Szittner, Arthur E. H. Bentlage, A. Robin Temming, David E. Schmidt, Remco Visser, Suzanne Lissenberg-Thunnissen, Juk Yee Mok, Wim J. E. van Esch, Myrthe E. Sonneveld, Erik L. de Graaf, Manfred Wuhrer, Leendert Porcelijn, Masja de Haas, C. Ellen van der Schoot, Gestur Vidarsson
Summary: The core fucosylation in anti-HPA-1a IgG greatly influences its binding to leukocyte IgG-Fc receptors IIIa/b. A cellular surface plasmon resonance imaging technique was developed to quantify the biological activity of IgG antibodies targeting cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Hematology
Julia Alm, Yalin Duong, Sandra Wienzek-Lischka, Nina Cooper, Sentot Santoso, Ulrich J. Sachs, Volker Kiefel, Gregor Bein
Summary: Most cases of FNAIT are caused by maternal anti-HPA-1a antibodies, while anti-HPA-5b antibodies are the second most common antibodies. However, there is no evidence supporting the idea that anti-HPA-5b antibodies cause severe thrombocytopenia or bleeding complications.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Obstetrics & Gynecology
Thijs W. de Vos, Masja de Haas, Dick Oepkes, Ratna N. G. B. Tan, C. Ellen van der Schoot, Sylke J. Steggerda, Linda S. de Vries, Enrico Lopriore, Jeanine M. M. van Klink
Summary: This study aimed to evaluate the long-term neurodevelopmental outcomes in children with fetal and neonatal alloimmune thrombocytopenia who were treated with antenatal intravenous immunoglobulin. The results showed that the risk of neurodevelopmental impairment in these children is comparable to that reported in the general population.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2022)
Article
Hematology
David Boehm, Sandra Wienzek-Lischka, Nina Cooper, Heike Berghoefer, Katja Mueller, Behnaz Bayat, Gregor Bein, Ulrich J. Sachs
Summary: In fetal/neonatal alloimmune thrombocytopenia (FNAIT), maternal alloantibodies against paternal human platelet antigens (HPA) lead to platelet destruction through the placenta. The extent of thrombocytopenia varies, and inflammation may play a role. In this study, inflammatory markers were measured in serum samples from neonates with low platelet counts, and it was found that systemic inflammation did not contribute significantly to thrombocytopenia in FNAIT. However, the antiangiogenic enzyme sFlt-1 released by the placenta correlated with platelet count in FNAIT cases, suggesting that placental inflammation may modulate disease severity.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Obstetrics & Gynecology
Siw L. Ernstsen, Maria T. Ahlen, Tiril Johansen, Eirin L. Bertelsen, Jens Kjeldsen-Kragh, Heidi Tiller
Summary: This study compared the outcomes of pregnancies with anti-human platelet antigen-1a-induced intracranial hemorrhage treated with intravenous immunoglobulin versus pregnancies without this treatment. The results showed that omitting antenatal intravenous immunoglobulin treatment in low-risk pregnancies does not increase the risk of neonatal intracranial hemorrhage.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2022)
Review
Hematology
Wendy Stam, Gabriela Elis Wachholz, Jose Maria de Pereda, Rick Kapur, Ellen van der Schoot, Coert Margadant
Summary: FNAIT is a pregnancy-associated condition caused by maternal alloantibodies against paternally-inherited platelet antigens, most frequently HPA-1a on integrin beta 3. The clinical effects range from no symptoms to fatal intracranial hemorrhage, but underlying pathophysiological determinants are poorly understood.
Article
Veterinary Sciences
L. Chantillon, B. Devriendt, B. De Jonge, J. Oostvogels, J. Coppens, M. L. Pas, J. Bokma, B. Pardon
Summary: This study reports on three calves from two different farms that were diagnosed with immune-mediated pancytopenia, which is clinically indistinguishable from BNP.
BMC VETERINARY RESEARCH
(2022)
Article
Hematology
Li Guo, Rick Kapur, Rukshana Aslam, Edwin R. Speck, Anne Zufferey, Yajing Zhao, Michael Kim, Alan H. Lazarus, Heyu Ni, John W. Semple
Article
Hematology
Hai Zhou, Yu Hou, Xuena Liu, Jihua Qiu, Qi Feng, Yawen Wang, Xu Zhang, Yanan Min, Lin Shao, Xinguang Liu, Guosheng Li, Lizhen Li, Lei Yang, Shuqian Xu, Heyu Ni, Jun Peng, Ming Hou
THROMBOSIS AND HAEMOSTASIS
(2015)
Article
Multidisciplinary Sciences
June Li, Dianne E. van der Wal, Guangheng Zhu, Miao Xu, Issaka Yougbare, Li Ma, Brian Vadasz, Naadiya Carrim, Renata Grozovsky, Min Ruan, Lingyan Zhu, Qingshu Zeng, Lili Tao, Zhi-min Zhai, Jun Peng, Ming Hou, Valery Leytin, John Freedman, Karin M. Hoffmeister, Heyu Ni
NATURE COMMUNICATIONS
(2015)
Review
Biochemistry & Molecular Biology
Yiming Wang, Heyu Ni
CELLULAR AND MOLECULAR LIFE SCIENCES
(2016)
Review
Medical Laboratory Technology
Xiaohong Ruby Xu, Dan Zhang, Brigitta Elaine Oswald, Naadiya Carrim, Xiaozhong Wang, Yan Hou, Qing Zhang, Christopher Lavalle, Thomas McKeown, Alexandra H. Marshall, Heyu Ni
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
(2016)
Review
Hematology
Yiming Wang, Reid C. Gallant, Heyu Ni
CURRENT OPINION IN HEMATOLOGY
(2016)
Article
Endocrinology & Metabolism
Alison Cameron-Vendrig, Adili Reheman, M. Ahsan Siraj, Xiaohong Ruby Xu, Yiming Wang, Xi Lei, Talat Afroze, Eric Shikatani, Omar El-Mounayri, Hossein Noyan, Ralph Weissleder, Heyu Ni, Mansoor Husain
Review
Pediatrics
Darko Zdravic, Issaka Yougbare, Brian Vadasz, Conglei Li, Alexandra H. Marshall, Pingguo Chen, Jens Kjeldsen-Kragh, Heyu Ni
SEMINARS IN FETAL & NEONATAL MEDICINE
(2016)
Article
Hematology
Xiaohong Ruby Xu, George M. Yousef, Heyu Ni
Article
Multidisciplinary Sciences
Jihua Qiu, Xuena Liu, Xiaoqing Li, Xu Zhang, Panpan Han, Hai Zhou, Linlin Shao, Yu Hou, Yanan Min, Zhangyuan Kong, Yawen Wang, Yu Wei, Xinguang Liu, Heyu Ni, Jun Peng, Ming Hou
SCIENTIFIC REPORTS
(2016)
Article
Multidisciplinary Sciences
Louise J. Eltringham-Smith, Ruoying Yu, Syed M. Qadri, Yiming Wang, Varsha Bhakta, Edward L. Pryzdial, Jeffrey R. Crosby, Heyu Ni, William P. Sheffield
SCIENTIFIC REPORTS
(2019)
Article
Hematology
Alexander Leatherdale, D'Andra Parker, Subia Tasneem, Yiming Wang, Dominique Bihan, Arkadiusz Bonna, Samir W. Hamaia, Peter L. Gross, Heyu Ni, Bradley W. Doble, David Lillicrap, Richard W. Farndale, Catherine P. M. Hayward
Summary: Multimerin 1 enhances platelet adhesion synergistically with other triple-helical collagen peptides by binding to highly conserved GPAGPOGPX motifs in fibrillar collagens. Moreover, Mmrn1-deficient mice showed impaired platelet adhesion and thrombus formation in the ferric chloride injury model.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Peter A. A. Norris, Gurleen Kaur, Ramsha Khan, Guangheng Zhu, Heyu Ni, Alan H. Lazarus
Summary: Anti-CD44 exhibits anti-inflammatory effects in murine ITP by inhibiting macrophage phagocytosis through blockade of Fc gamma R, potentially serving as an alternative to IVIg. The specific Fc gamma R blockade mechanism of anti-CD44 contributes to its therapeutic efficacy in ITP models, highlighting its potential as a treatment option.
Article
Biochemistry & Molecular Biology
Ming Liu, Gan Wang, Runjia Xu, Chuanbin Shen, Heyu Ni, Ren Lai
Summary: Soy isoflavones genistein and daidzein were found to inhibit thrombosis formation, particularly under high shear force. They interact with 14-3-3ζ and suppress multiple platelet activation pathways and outside-in signaling transduction. These findings suggest that 14-3-3ζ is a novel target for genistein and daidzein in platelet inhibition.
Article
Chemistry, Medicinal
Wenjing Ma, Zackary Rousseau, Sladjana Slavkovic, Chuanbin Shen, George M. M. Yousef, Heyu Ni
Summary: This study found that Doxorubicin induced platelet activation and increased macrophage phagocytosis of platelets, leading to accelerated platelet clearance. Salvianolic acid C (SAC), derived from Danshen root, was found to inhibit Doxorubicin-induced platelet activation more effectively than current anti-platelet drugs. Doxorubicin also enhanced platelet-cancer cell interaction, which was alleviated by SAC.